Juvelook
Juvelook is a family of hybrid injectable products combining poly-D,L-lactic acid (PDLLA) particles with hyaluronic acid (HA). The current Korean family includes five named presentations with three total-content tiers. Product name, PDLLA quantity, HA quantity, particle characteristics, preparation, and intended use must remain visible.
Juvelook should not be treated as one concentration, and Juvelook Volume should not be treated as a casual synonym for every 200 mg presentation.
Quick reference
Section titled “Quick reference”| Field | Juvelook family |
|---|---|
| Material system | PDLLA particles + HA |
| Current Korean family | Juvelook i, Juvelook Skin, Juvelook, Juvelook Volume, Juvelook G |
| Listed total content | 30 mg, 50 mg, or 200 mg depending on presentation |
| Product form | Product-specific dry presentation requiring preparation |
| Immediate-effect interpretation | Must account for HA, prepared fluid, and PDLLA as different contributors |
| Company | VAIM |
| Main comparison | AestheFill is PDLLA + CMC rather than the same PDLLA + HA system |
VAIM’s current Korean product page lists the compositions and intended-use wording for all five presentations (Juvelook product information 🔗).
Current Korean product family
Section titled “Current Korean product family”| Presentation | PDLLA | HA | Total listed content | Company-reported particle context |
|---|---|---|---|---|
| Juvelook i | 25.5 mg | 4.5 mg | 30 mg | Company interview describes a nominal 20 μm particle size |
| Juvelook Skin | 25.5 mg | 4.5 mg | 30 mg | Not identified on the reviewed product page |
| Juvelook | 42.5 mg | 7.5 mg | 50 mg | Company interview describes a nominal 25 μm particle size |
| Juvelook Volume | 170 mg | 30 mg | 200 mg | Company interview describes a nominal 40 μm particle size |
| Juvelook G | 170 mg | 30 mg | 200 mg | Company interview describes a nominal 65 μm particle size |
The composition values come from VAIM’s official product page. The nominal particle-size statements come from a 2025 interview published on the company’s media page and should be treated as company-reported product characterization, not as an independent comparative clinical result (VAIM interview 🔗).
The same PDLLA and HA quantities do not prove that Juvelook i and Juvelook Skin—or Juvelook Volume and Juvelook G—are interchangeable. Product naming and particle characterization indicate that formulation identity extends beyond total content.
Approved wording and broader clinical discussion
Section titled “Approved wording and broader clinical discussion”VAIM’s Korean product page describes the intended use as subcutaneous injection of polylactide and HA for temporary improvement of adult facial wrinkles through physical restoration.
That approved wording should remain separate from company media, published studies, and common clinical discussion involving:
- fine lines
- pores or texture
- acne scars
- tear troughs
- nasolabial folds
- broader volumization
- body use
A study or company presentation involving one of these objectives does not make it a universal approved indication for every Juvelook product.
Preparation is presentation-specific
Section titled “Preparation is presentation-specific”Published Juvelook studies use heterogeneous preparation methods. For example, a preliminary whole-face study used the 50 mg Juvelook presentation and a 10 mL mixture containing additional HA, lidocaine, and saline (Journal of Cosmetic Dermatology 🔗). A 2026 nasolabial-fold case series instead reported a 6 mL saline preparation (Juvelook nasolabial-fold case series 🔗).
These are study protocols, not evidence that either method:
- is the controlling Korean IFU
- applies to all five presentations
- can be transferred between anatomical areas
- produces equivalent particle distribution or clinical behavior
Document the exact product, reconstitution liquid, total volume, additives, preparation method, standing time, device, anatomy, and source type whenever technique is discussed.
Immediate and delayed components
Section titled “Immediate and delayed components”Juvelook is a hybrid product. Its clinical sequence should not be summarized as if HA and PDLLA perform the same role.
| Phase | Interpretation |
|---|---|
| Immediately after injection | Prepared fluid, HA, edema, and physical distribution can all affect appearance |
| Early follow-up | Fluid-related and inflammatory changes evolve |
| Later follow-up | Published discussion focuses on tissue response associated with the PDLLA component |
The presence of HA does not make the whole implant equivalent to an HA-only gel or establish complete reversibility with hyaluronidase.
Clinical evidence: product and protocol must stay visible
Section titled “Clinical evidence: product and protocol must stay visible”The available literature includes small prospective or preliminary studies of the 50 mg Juvelook presentation in different treatment contexts. One preliminary facial-rejuvenation study used PDLLA 42.5 mg plus HA 7.5 mg, while a 2026 nasolabial-fold case series included 20 patients with three-month follow-up after the final session.
These studies can inform product-specific questions, but limitations include:
- small cohorts
- short follow-up in some studies
- absence of a comparator in case series
- heterogeneous preparation and delivery
- anatomy-specific results
Do not extrapolate “no nodules observed” in a small, short study into a class-wide or product-family guarantee.
Company and product roles
Section titled “Company and product roles”| Role | Supported relationship |
|---|---|
| Brand and product family | Juvelook |
| Company | VAIM |
| Korean product information source | VAIM official Juvelook site |
| Legal manufacturer and approval holder | Verify from the exact product registration and IFU |
| Regional brand name or distributor | Market-specific |
Regional names such as Lenisna or other distributor-facing identities require separate verification. Shared company or PDLLA technology does not prove identical presentation, label, or commercial role.
The VAIM company page distinguishes the Korean brand family from international manufacturer, registration, and distributor records.
Safety and limitations
Section titled “Safety and limitations”Juvelook products are particulate hybrid implants. Safety interpretation should preserve:
- exact presentation
- particle characteristics
- preparation homogeneity
- placement and anatomy
- HA-related and PDLLA-related components
- vascular-event risk
- early versus delayed nodules
- inflammatory signs and infection
The smaller nominal particle size of one presentation should not be rewritten as proof of safety in thin or high-risk anatomy.
Nearby reference pages
Section titled “Nearby reference pages”- Skin quality separates elasticity, hydration, roughness, and subjective ratings.
- Immediate vs delayed effects keeps prepared fluid, HA, edema, and PDLLA visible.
- South Korea regulation preserves the Korean intended-use wording and product-family boundary.
- Clinical practice framework connects exact presentation to screening, consent, and follow-up.
- Nodules and delayed reactions explains why HA and PDLLA components remain visible in assessment.
- AestheFill vs Juvelook keeps PDLLA, HA, and exact presentation visible.
- Ready-to-use vs reconstituted explains why preparation cannot be inferred from the material acronym.
- PDLLA explains the material family and why hybrid composition matters.
- AestheFill provides the closest initial PDLLA formulation comparison.
- Radiesse separates a mineral-microsphere and CMC-carrier implant from PDLLA + HA.
- Collagen Stimulators maps the wider product graph.